Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Recruiting · NCT07362017 · Interventional (participants receive a specific treatment) · Lead sponsor: Vanda Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
Ponesimod
What this trial is about
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male and female subjects aged 18-65 years, inclusive
- BMI \>18 and \<40
- Minimum affected BSA of 10%
- PASI score ≥ 12
- PGA ≥ 3
- Diagnosed with moderate-to-severe plaque psoriasis
Exclusion criteria
- Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
- History of an allergic reaction or known and/or significant sensitivity to study drug
Where it is running
4 locations listed across 4 US states.
- Vanda Investigational Site - Glendale, Arizona, United States
- Vanda Investigational Site - Fremont, California, United States
- Vanda Investigational Site - Rochester, New York, United States
- Vanda Investigational Site - Spokane, Washington, United States